Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 201 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]
2. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
4.Enlace a cita original Cita con resumen
Amundsen S, Ovrebo TG, Amble NMS, Poole AC, Nordeng H. Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. Eur J Clin Pharmacol 2016;72:1525-35. [Ref.ID 101013]
5.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
8. Cita con resumen
Anónimo. FDA warns about several safety issues with opioid pain medicines; requires label changes. U.S. Food and Drug Administration 2016:22 de marzo. [Ref.ID 100078]
9. Cita con resumen
Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ 2014;348:g2285. [Ref.ID 97939]
10. Cita con resumen
Anónimo. Topiramate approved for migraine prevention in adolescents. U.S. Food and Drug Administration 2014:28 de marzo. [Ref.ID 97390]
11. Cita con resumen
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626. [Ref.ID 97343]
12. Cita con resumen
Anónimo. Valvulopathies d'origine médicamenteuse. Prescrire 2013;33:668-72. [Ref.ID 96188]
13. Cita con resumen
Kuehn BM. Valproate pregnancy risks. JAMA 2013;309:2542. [Ref.ID 95735]
14. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
15. Cita con resumen
Anónimo. Serotonergic medicines. Risk of reversible cerebral vasoconstriction syndrome (RCVS). New Zealand. WHO Pharmaceuticals Newsletter 2012;4:11-2. [Ref.ID 93679]
16. Cita con resumen
Anónimo. Prises de poids d'origine médicamenteuse. Prescrire 2011;31:748-52. [Ref.ID 91601]
17. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
18.
Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55. [Ref.ID 89176]
19.
Loder E. Triptan therapy in migraine. N Engl J Med 2010;363:63-70. [Ref.ID 88759]
20. Cita con resumen
Beau-Salinas F, Jonville-Bera AP, Cissoko H, Bensouda-Grimaldi L, Autret-Leca E. Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol 2010;66:413-7. [Ref.ID 88245]
Seleccionar todas
 
 1 a 20 de 201 siguiente >>